From Transcriptomic Clinical Evidence to Human Proteomics-Driven Modality Discovery: Building Next-Generation Platforms for ADC, TPD & Dual-Targeting siRNA

• Tracing how RAPTOR AI v1.0 platform translated transcriptomic signatures into prioritized drug, indication, and combination-therapy hypotheses for experimental evaluation and clinical development
• Assessing experimental and early clinical evidence from OC212e to examine how the transcriptomic hypothesis translated into a clinically relevant program and how insights informed RAPTOR platform evolution
• Introducing RAPTOR AI v2.0 to integrate clinically annotated, human samplederived proteomic and multi-omic data to support modality-specific target discovery, target-pair selection and therapeutic development 

Speakers:

Jihoon Kang

Co-Chief Executive Officer

ONCOCROSS